Co-Founder, LEUVAS Therapeutics
Co-Founder, VENETO Pharma
Professor of Anatomy, University of Verona
Dr. Fabene’s academic research is focused on understanding the behavioral and cognitive correlates of non-neuronal to neuronal cell cross-modulation both in baseline and in pathological conditions, such as epilepsy. His interest over the last decade has focused on studying the molecular and cellular basis of epileptogenic processes in models of epilepsy.
Paolo has made seminal discoveries in the field, laying the groundwork for the development of therapeutics that not only block seizure, but also prevent epileptogenesis. Drs. Fabene, Butcher and Constantin made the initial discovery that seizures induce expression of vascular adhesion molecules and enhanced leukocyte-endothelial interaction, and that inhibition these interactions prevented BBB leakage, markedly reduced seizures, and prevented development of epilepsy. The therapy developed in the Fabene lab prevented seizures and avoided the chronic alterations in the formation of blood-brain barrier, blocking the excitability of neurons that favored seizures (Fabene et al, Nat Med., 2008). Nature Medicine, Nature, Nature Reviews in Drug Discovery and other leading journal published editorials focused on these results, thus indicating the impact of these results on the scientific community.
Dr. Fabene earned his PhD in Neuroscience in 2002 and had a highly productive postdoctoral fellowship at the University of Verona, leading to his founding of the laboratory of integrated biopotential and behavior at the University of Verona, which he supervises. Paolo is a member of the National Committee for Experimental Epileptology of the Italian League against Epilepsy (LICE) and the General Committee of the Italian Society of Neuroscience (Società Italiana di Neuroscienze).
1: Bertini et al New players in the neurovascular unit: insights from experimental and clinical epilepsy. Neurochem Int. 2013 Dec;63(7):652-9.
2: Fabene PF, Laudanna C, and Constantin G. Leukocyte trafficking mechanisms in epilepsy. Mol Immunol. 2013 Aug;55(1):100-4.
3: Fabene PF, et al . A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008 Dec;14(12):1377-83.
4: Dedeurwaerdere et al. Finding a better drug for epilepsy: antiinflammatory targets. Epilepsia. 2012 Jul;53(7):1113-8.
5: Fabene et al., The emerging role for chemokines in epilepsy. J Neuroimmunol. 2010 Jul 27;224(1-2):22-7.
6. Fabene et al, (2008) A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008 Dec;14(12):1377-83.